Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells $188,500.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 65,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $2.90, for a total value of $188,500.00. Following the completion of the sale, the insider now directly owns 30,484 shares in the company, valued at $88,403.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Fractyl Health Trading Down 2.4 %

Shares of GUTS stock opened at $2.79 on Friday. The company has a 50 day moving average price of $3.32 and a 200 day moving average price of $5.53. Fractyl Health, Inc. has a one year low of $1.74 and a one year high of $14.50. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10. The firm had revenue of $0.04 million for the quarter. Analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Fractyl Health

A number of institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Fractyl Health during the 2nd quarter valued at $61,000. Massachusetts Financial Services Co. MA raised its position in Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after purchasing an additional 25,829 shares during the period. Rhumbline Advisers acquired a new position in shares of Fractyl Health during the second quarter worth about $32,000. M28 Capital Management LP purchased a new stake in shares of Fractyl Health in the first quarter worth about $13,735,000. Finally, American International Group Inc. acquired a new stake in shares of Fractyl Health in the first quarter valued at about $9,911,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.